Drug intelligence / Profile preview

Pneumo 23

Development stage
Phase 4
Lead developer
Merck
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Subcutaneous
01

Overview

**Pneumo 23** is a Sanofi 23-valent pneumococcal capsular polysaccharide vaccine for active immunization against disease caused by the *Streptococcus pneumoniae* serotypes represented in the product. It contains purified capsular polysaccharides from 23 pneumococcal serotypes and induces serotype-specific anti-capsular antibody responses that support opsonization and immune clearance of pneumococci. It is a non-conjugated polysaccharide vaccine, not a pneumococcal conjugate vaccine, and is used to help prevent pneumococcal infections, including invasive disease and pneumococcal pneumonia, in individuals aged 2 years and older for whom vaccination is indicated. ([registrasiobat.pom.go.id](https://registrasiobat.pom.go.id/files/assesment-reports/obat_baru/Pneumo23.pdf))

Brand names
Pneumo 23Pneumo23Pneumo-23
Other names
Pneumo23Pneumo-23Pneumo 23
02

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on Pneumo 23.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pneumo 23.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call